NWM
CGTX icon

Nova Wealth Management’s Cognition Therapeutics CGTX Stock Holding History

Nova Wealth Management’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-500
Closed -$675 – 583
2025
Q3 		$675 Buy
+500
New +$682 ﹤0.01% 564

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

Nova Wealth Management's CGTX Position: Q4 2025 in Review

Nova Wealth Management sold out of Cognition Therapeutics (CGTX) in Q4 2025, closing a stake of 500 shares — an estimated $675 sold.

Nova Wealth Management first reported a position in CGTX in Q3 2025 and held it in 1 quarter. The position peaked at $675 in Q3 2025. 78 funds tracked by Wall St. Rank hold CGTX as of Q4 2025.

  • Nova Wealth Management reported no remaining Cognition Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Nova Wealth Management sold 500 Cognition Therapeutics shares in Q4 2025, an estimated $675.
  • Nova Wealth Management first reported a position in Cognition Therapeutics in Q3 2025 and held it in 1 quarter.
  • Nova Wealth Management's Cognition Therapeutics position peaked at $675 in Q3 2025.
  • 78 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q4 2025.

Based on Nova Wealth Management's 13F filing for Q4 2025, filed 14 Jan 2026.